Literature DB >> 10562498

Characterization of intertypic recombinants of the Epstein-Barr virus from the body-cavity-based lymphomas cell lines BC-1 and BC-2.

A J Aguirre1, E S Robertson.   

Abstract

Epstein-Barr Virus (EBV) can infect and transform human B-lymphocytes and has been associated with numerous human malignancies. Two distinct types of EBV have been described, EBV-1 and EBV-2. Whereas type 1 is known to be most widespread throughout the healthy adult population, type 2 EBV has been shown to be significantly present in certain T-cell immunocompromised patients. Some evidence also suggests that such immune impairment promotes coinfection with multiple strains of EBV and fosters the development of intertypic recombinant viruses. In this work, we have analyzed two established body-cavity-based lymphoma or primary effusion lymphoma cell lines, BC-1 and BC-2, for the presence of intertypic EBV recombinants. Using PCR primers to amplify across several markers in the genome, we have typed the BC-1 and BC-2 EBV at these loci. Immunoblot analysis of the EBNA1 protein expressed by these cell lines also suggests a change in EBV typing at this locus in these genomes. Additionally, we have analyzed the expression patterns of the latent EBNA proteins from these viruses and performed Southern blot analysis of the BamHI- and EcoRI-digested genomes to detect variations occurring from type I and II genomes. On the basis of these data, we suggest that the genomes of EBV in BC-1 and BC-2 are intertypic recombinants of type 1 and type 2 EBV genomes. This work corroborates other reports that intertypic EBV recombinants occur in the immunocompromised population. It is likely that intertypic recombination is a mechanism by which novel variants of EBV emerge having selective advantages over a strictly type 1 or type 2 strain. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10562498     DOI: 10.1006/viro.1999.0015

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  6 in total

1.  Epstein-Barr virus recombinants from BC-1 and BC-2 can immortalize human primary B lymphocytes with different levels of efficiency and in the absence of coinfection by Kaposi's sarcoma-associated herpesvirus.

Authors:  A J Aguirre; E S Robertson
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells.

Authors:  A Krithivas; D B Young; G Liao; D Greene; S D Hayward
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

Review 3.  The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal.

Authors:  Cindy M Chang; Kelly J Yu; Sam M Mbulaiteye; Allan Hildesheim; Kishor Bhatia
Journal:  Virus Res       Date:  2009-07-23       Impact factor: 3.303

4.  Target DNA detection and quantitation on a single cell with single base resolution.

Authors:  Tania Konry; Adam Lerner; Martin L Yarmush; Irina V Smolina
Journal:  Technology (Singap World Sci)       Date:  2013-09

5.  Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting Rta: a potential mechanism for virus-mediated control of latency.

Authors:  Ke Lan; Daniel A Kuppers; Subhash C Verma; Erle S Robertson
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

6.  Coupled transcriptome and proteome analysis of human lymphotropic tumor viruses: insights on the detection and discovery of viral genes.

Authors:  Lindsay R Dresang; Jeremy R Teuton; Huichen Feng; Jon M Jacobs; David G Camp; Samuel O Purvine; Marina A Gritsenko; Zhihua Li; Richard D Smith; Bill Sugden; Patrick S Moore; Yuan Chang
Journal:  BMC Genomics       Date:  2011-12-20       Impact factor: 3.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.